NCT02174835View on ClinicalTrials.gov

A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Healthy
Interventions
DRUG

AVP-786

DRUG

AVP-923

Trial Locations (1)

5000

CMAX, Adelaide

Sponsors
All Listed Sponsors
lead

Avanir Pharmaceuticals

INDUSTRY

NCT02174835 - A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers | Biotech Hunter | Biotech Hunter